Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00441883 · ClinicalTrials.gov registry record · Phase 2

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

A Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
Phase 2
Development phase
176
Enrollment target
19
Study locations

NCT00441883 is a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 176 participants, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (36% lower). The trial reports 19 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00441883, a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
176 participants
Enrollment target
19
Study locations

Study Summary

This study will evaluate the safety and efficacy of PF 03187207.

Conditions Studied

Ocular Hypertension Primary Open Angle Glaucoma Pigmentary Glaucoma Pseudoexfoliative Glaucoma

Interventions

  • DRUG PF-03187207 and Latanoprost Vehicle
  • DRUG Latanoprost 0.005% and PF-03187207 Vehicle

Study Locations (19)

California

  • Pfizer Investigational Site - Artesia
  • Pfizer Investigational Site - Newport Beach
  • Pfizer Investigational Site - Petaluma
  • Pfizer Investigational Site - Poway

Florida

  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Ormond Beach

Georgia

  • Pfizer Investigational Site - Atlanta
  • Pfizer Investigational Site - Atlanta

North Carolina

  • Pfizer Investigational Site - Charlotte
  • Pfizer Investigational Site - High Point

Pennsylvania

  • Pfizer Investigational Site - Cranberry Township
  • Pfizer Investigational Site - Pittsburgh

Connecticut

  • Pfizer Investigational Site - Danbury

Indiana

  • Pfizer Investigational Site - Evansville

Kentucky

  • Pfizer Investigational Site - Louisville

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2007-03
Est. Completion 2008-07
Phase Phase 2

Sponsor

Bausch & Lomb Incorporated

174 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00441883

The ClinicalTrials.gov registry entry for NCT00441883 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (36% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which PF-03187207 and Latanoprost Vehicle is the first listed.

NCT00441883 reports 19 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00441883 about?

NCT00441883 is a clinical study titled "Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma". This study will evaluate the safety and efficacy of PF 03187207.

What is the current status of trial NCT00441883?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2007-03. Estimated completion is 2008-07.

What conditions does trial NCT00441883 study?

This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma.

What interventions are being tested in trial NCT00441883?

The interventions under investigation include: PF-03187207 and Latanoprost Vehicle (DRUG), Latanoprost 0.005% and PF-03187207 Vehicle (DRUG).

Who is sponsoring clinical trial NCT00441883?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00441883 being conducted?

This trial has 19 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ocular Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ocular Hypertension

All registered trials for this condition

Primary Open Angle Glaucoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.